http://www.newswire.ca/releases/September2002/30/c6275.html
|
|
|
Canada NewsWire | |
|
|
||||
Attention Business Editors:
TRADING SYMBOLS - NASDAQ - "IDBE", TSE - "IDB"
VANCOUVER, Sept. 30 /CNW/ - ID Biomedical announced today that Dr. Scott
Halperin of the Clinical Trials Research Center at IWK Health Centre and
Dalhousie University in Halifax, Nova Scotia, presented Phase I Clinical Trial
results for the FluINsure(TM) flu vaccine at the 42nd Interscience Conference
on Antimicrobial Agents and Chemotherapy (ICAAC) in San Diego, CA. The
FluINsure flu vaccine is the Company's intranasally administered, non-living
vaccine for the prevention of influenza.
The clinical trial demonstrated that FluINsure(TM), which is a trivalent
product, was strongly immunogenic. Statistically-significant increases in both
serum hemagglutination inhibiting (HAI) antibody and in virus-specific
secretory IgA antibodies in the nose were shown for all three types of
influenza viruses (A/H1N1, A/H3N2, and B) represented in the vaccine. Serum
HAI antibody is an accepted correlate of immunity to influenza, and nasal
secretory IgA antibody responses have received attention as an additional
marker of disease resistance induced by live, attenuated nasal influenza
vaccines. In addition, FluINsure was well-tolerated by healthy adults in this
randomized, double-blinded, and placebo-controlled trial. Only mild and short-
lived runny nose was associated with the active vaccine when compared to
placebo. "Based on the results of this trial, the FluINsure flu vaccine
appears to be quite competitive, in terms of both safety and immunogenicity,
with other nasal flu vaccines," said Dr. Halperin.
"These are very encouraging results," said Dr. Louis Fries, Vice
President for Clinical and Regulatory Affairs. "Across all subjects who got
active vaccine, the average increase in serum HAI antibody levels to all three
viruses was 3.2-fold. However, if you consider those subjects who entered the
study with levels of serum HAI antibody below the presumed protective level -
those who needed protection - the average increase was 5.3-fold. Virus-
specific nasal IgA responses, which are technically harder to measure, were
also strong in both all subjects and in subjects without clear pre-existing
immunity, averaging 2.3 to 2.6-fold. While the two-dose group did have larger
antibody rises, we were pleased to see significant immune responses in every
treatment group. Overall, we saw significant, potentially protective, serum
and/or nasal antibody responses in 71, 87, and 90% of subjects who entered the
study without evidence of existing immunity to the A/H1N1, A/H3N2, or B
viruses, respectively."
The FluINsure flu vaccine is currently undergoing Phase II testing to
further define an optimal dosing regimen. Results from the Phase II study are
expected in Q4 2002. Subsequently, the Company plans to evaluate the vaccine
in one or more challenge trials.
FluINsure is based on the Company's proprietary Proteosome(TM) vaccine
delivery/adjuvant technology. The flu vaccine is created by combining
Proteosome proteins with a purified preparation of influenza proteins that
includes the hemagglutinin protein. Importantly, unlike some other nasal
influenza vaccines in development, FluINsure contains no live viruses.
Intranasal vaccines based on the Proteosome delivery system, and incorporating
a variety of different antigens, have now been tested in over 360 people and
have had a very encouraging safety profile.
About ID Biomedical
ID Biomedical is a North American based biotechnology company focused on
the development of proprietary subunit vaccine products, including those based
on its Proteosome(TM) platform intranasal adjuvant/delivery technology. ID
Biomedical has also developed a proprietary genomics analysis system, Cycling
Probe(TM) Technology.
ID Biomedical is developing subunit vaccines for the prevention of a
number of different diseases. The Company's lead products in clinical
development are the FluINsure(TM) intranasal influenza (flu) vaccine and the
StreptAvax(TM) group A streptococcal vaccine. Additionally, the Company has a
number of vaccines in preclinical development.
ID Biomedical is licensing Cycling Probe Technology as well as its broad
patents in signal amplification to the genomics and diagnostic industry for
further products and technology development. Several companies have obtained
rights to ID Biomedical's patent portfolio.
The foregoing information contains so-called forward-looking statements.
These include statements about ID Biomedical's expectations, beliefs,
intentions or strategies for the future, which it indicates by words or
phrases such as "anticipate", "expect", "intend", "plan", "will", "we
believe", "ID Biomedical believes", "management believes" and similar
language. All forward-looking statements are based on ID Biomedical's current
expectations and are subject to risks uncertainties and to assumptions made.
Important factors that could cause actual results to differ materially from
those expressed or implied by such forward-looking statements include: (i) the
ability to successfully complete preclinical and clinical development of its
products; ii) the ability to obtain and enforce timely patent and intellectual
property protection for its technology and products; iii) the ability to
avoid, either by product design, licensing arrangement or otherwise,
infringement of third parties' intellectual property; iv) decisions, and the
timing of decisions, made by the health regulatory agencies regarding approval
of its products for human testing; v) the ability to complete and maintain
corporate alliances relating to the development and commercialization of its
technology and products; vi) market acceptance of its technology and product;
and (vii) the competitive environment and impact of technological change. ID
Biomedical bases its forward-looking statements on information currently
available to it, and assumes no obligation to update them.
-30-
For further information: ID Biomedical Corporation, Dean Linden, Manager, Corporate Communications, (604) 431-9314, www.idbiomedical.com; To request a free copy of this organization's annual report, please go to http://www.newswire.ca and click on reports@cnw.
 |
|
 |
 |
 |
|
 |
 |
 |
|
 |
 |
 |
General Inquiries - cnw@newswire.ca Technical Issues - webmaster@newswire.ca © 2002 Canada NewsWire Ltd. All rights reserved. |
 |
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.